Jim Belushi sings the RCG blues for Savient

Share this article:
Jim Belushi sings the RCG blues for Savient
Jim Belushi sings the RCG blues for Savient
Krystexxa maker Savient has recruited Jim Belushi for an awareness-raising campaign dubbed “Check Out Your Gout.”

The unbranded effort, launching in Chicago this week to coincide with the American College of Rheumatology meeting, features the actor, who suffers from gout, in video PSAs at CheckOutYourGout.com. TV and radio PSAs will broadcast nationally.

The campaign aims to educate consumers about a severe form of gout called refractory chronic gout, or RCG, which affects around 120,000 Americans – a fraction of the 8 million gout sufferers in the US. Krystexxa, approved late last year and launched in early 2011, is indicated for RCG but not the more general form. RCG may be diagnosed when uric acid levels remain high and symptoms persist despite available conventional therapies, and symptoms may be debilitating, due to the frequency and severity of episodes, the recurrent painful gout attacks and the disfigurement associated with the condition.

“Gout continues to be widely misperceived and overlooked,” said Louis Ferrari, SVP commercial operations North America. “Our hope is that through the ‘Check Out Your Gout' campaign Savient, together with Jim, can increase awareness and understanding of gout and RCG.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...